Biora rises as FDA greenlights human trials for bowel disease treatment

Biora Therapeutics

30/11/2023 23:04

** Shares of biotech company Biora Therapeutics  BIOR.O 
surges ~65.3% to $2.04 after the bell
    ** Co says the US FDA has cleared its application seeking to
begin clinical trials on its drug/device combination, BT-600,
for the treatment of ulcerative colitis 
    ** Says it will complete the activities required by FDA and
the trial site prior to enrolling the first subject in its
early-stage trial in the US in the coming weeks
    ** Ulcerative colitis is an inflammatory bowel disease that
causes irritation, inflammation and ulcers in the lining of the
large intestine
    ** Up to last close, stock down 62.3% YTD

 (Reporting by Christy Santhosh)
 ((Christy.Santhosh@thomsonreuters.com))